Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 68Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Solid Tumor 2Rectal Neoplasms 2Prostatic Neoplasms 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Carcinoma, Ductal, Breast 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Neoplasms, Unknown Primary 1Metastatic HER2-Positive Breast Cancer 1Lung Neoplasms 1Her2-Positive Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Elderly Metastatic Breast Cancer Population 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Biliary Tract Neoplasms 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × pertuzumab × Clear all
NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Mayo Clinic

Phase 2 Completed
7 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00058539 2015-06-23

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

Genentech, Inc.

Phase 2 Completed
42 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡